163 related articles for article (PubMed ID: 36428669)
1. The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor.
Atzori MG; Ceci C; Ruffini F; Scimeca M; Cicconi R; Mattei M; Lacal PM; Graziani G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428669
[TBL] [Abstract][Full Text] [Related]
2. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
[TBL] [Abstract][Full Text] [Related]
4. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
[TBL] [Abstract][Full Text] [Related]
5. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.
Atzori MG; Tentori L; Ruffini F; Ceci C; Bonanno E; Scimeca M; Lacal PM; Graziani G
J Pharmacol Exp Ther; 2018 Jan; 364(1):77-86. PubMed ID: 29025978
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells.
Lacal PM; Atzori MG; Ruffini F; Tentori L; Graziani G
Oncol Rep; 2018 May; 39(5):2261-2269. PubMed ID: 29512738
[TBL] [Abstract][Full Text] [Related]
7. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A.
Roy H; Bhardwaj S; Babu M; Jauhiainen S; Herzig KH; Bellu AR; Haisma HJ; Carmeliet P; Alitalo K; Ylä-Herttuala S
Hum Gene Ther; 2005 Dec; 16(12):1422-8. PubMed ID: 16390273
[TBL] [Abstract][Full Text] [Related]
9. Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression.
Ruffini F; Failla CM; Orecchia A; Bani MR; Dorio AS; Fortes C; Zambruno G; Graziani G; Giavazzi R; D'Atri S; Lacal PM
Br J Dermatol; 2011 May; 164(5):1061-70. PubMed ID: 21198538
[TBL] [Abstract][Full Text] [Related]
10. Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.
Pagani E; Ruffini F; Antonini Cappellini GC; Scoppola A; Fortes C; Marchetti P; Graziani G; D'Atri S; Lacal PM
Int J Oncol; 2016 Apr; 48(4):1581-9. PubMed ID: 26846845
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
12. Neuropilin-1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1.
Colotti G; Failla CM; Lacal PM; Ungarelli M; Ruffini F; Di Micco P; Orecchia A; Morea V
FEBS J; 2022 Jan; 289(1):183-198. PubMed ID: 34252269
[TBL] [Abstract][Full Text] [Related]
13. VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody.
Micheli L; Parisio C; Lucarini E; Vona A; Toti A; Pacini A; Mello T; Boccella S; Ricciardi F; Maione S; Graziani G; Lacal PM; Failli P; Ghelardini C; Di Cesare Mannelli L
J Exp Clin Cancer Res; 2021 Oct; 40(1):320. PubMed ID: 34649573
[TBL] [Abstract][Full Text] [Related]
14. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
Carmeliet P; Moons L; Luttun A; Vincenti V; Compernolle V; De Mol M; Wu Y; Bono F; Devy L; Beck H; Scholz D; Acker T; DiPalma T; Dewerchin M; Noel A; Stalmans I; Barra A; Blacher S; VandenDriessche T; Ponten A; Eriksson U; Plate KH; Foidart JM; Schaper W; Charnock-Jones DS; Hicklin DJ; Herbert JM; Collen D; Persico MG
Nat Med; 2001 May; 7(5):575-83. PubMed ID: 11329059
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium.
Kaza E; Ablasser K; Poutias D; Griffiths ER; Saad FA; Hofstaetter JG; del Nido PJ; Friehs I
Cardiovasc Res; 2011 Feb; 89(2):410-8. PubMed ID: 20935166
[TBL] [Abstract][Full Text] [Related]
16. Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.
Ceci C; Atzori MG; Lacal PM; Graziani G
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085654
[TBL] [Abstract][Full Text] [Related]
17. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
19. Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis.
Jayasinghe C; Simiantonaki N; Kirkpatrick CJ
BMC Cancer; 2015 Mar; 15():104. PubMed ID: 25880726
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of circulating autoantibodies against VEGF-A, VEGFR-1 and PlGF in preeclampsia - A role in placental and vascular health?
Moe K; Heidecke H; Dechend R; Staff AC
Pregnancy Hypertens; 2017 Oct; 10():83-89. PubMed ID: 29153696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
